Studies have shown that in mouse models, inflammation-driven downregulation of EZH2 maintains SASP in CAFs by demethylating the H3K27me3 mark and enhances the formation of peritoneal tumors in gastric cancer (GC) through the JAK/STAT3 signaling pathway. Here, EZH2 is linked to gastric cancer.